Jaffet Jilu, Singh Vivek, Schrader Stefan, Mertsch Sonja
Laboratory of Experimental Ophthalmology, Department of Ophthalmology, Pius-Hospital, Carl von Ossietzky University, Oldenburg, Germany.
LV Prasad Eye Institute, Centre for Ocular Regeneration, Hyderabad, Telangana, India.
Curr Eye Res. 2024 Nov 7:1-14. doi: 10.1080/02713683.2024.2424265.
Dry eye disease (DED), a multifactorial disease of the lacrimal system, manifests itself in patients with various symptoms such as itching, inflammation, discomfort and visual impairment. In its most severe forms, it results in the breakdown of the vital tissues of lacrimal functional unit and carries the risk of vision loss. Despite the frequency of occurrence of the disease, there are no effective curative treatment options available to date. Treatment using stem cells and its secreted factors could be a promising approach in the regeneration of damaged tissues of ocular surface. The treatment using secreted factors as well as extracellular vesicles has been demonstrated beneficial effects in various ocular surface diseases. This review provides insights on the usage of stem cell derived exosomes as a promising therapy against LG dysfunction induced ADDE for ocular surface repair.
In order to gain an overview of the existing research in this field, literature search was carried out using the PubMed, Medline, Scopus and Web of Science databases. This review is based on 164 publications until June 2024 and the literature search was carried out using the key words "exosomes", "lacrimal gland regeneration", "exosomes in lacrimal dysfunction".
The literature and studies till date suggest that exosomes and other secreted factors from stem cells have demonstrated beneficial effects on damaged ocular tissues in various ocular surface diseases. Exosomal cargo plays a crucial role in regenerating tissues by promoting homeostasis in the lacrimal system, which is often compromised in severe cases of dry eye disease. Exosome therapy shows promise as a regenerative therapy, potentially addressing the lack of effective curative treatments available for patients with dry eye disease.
Stem cell-derived exosomes represent a promising, innovative approach as a new treatment option for ADDE. By targeting lacrimal gland dysfunction and enhancing ocular surface repair, exosome therapy offers potential for significant advances in dry eye disease management. Future research is needed to refine the application of this therapy, optimize delivery methods, and fully understand its long-term efficacy in restoring ocular health.
干眼疾病(DED)是一种泪液系统的多因素疾病,在患者中表现为多种症状,如瘙痒、炎症、不适和视力损害。在其最严重的形式中,它会导致泪液功能单位的重要组织受损,并存在视力丧失的风险。尽管该疾病发病率高,但迄今为止尚无有效的治愈性治疗方案。使用干细胞及其分泌因子进行治疗可能是眼表受损组织再生的一种有前景的方法。使用分泌因子以及细胞外囊泡进行治疗已在各种眼表疾病中显示出有益效果。本综述提供了关于干细胞衍生外泌体作为一种有前景的疗法用于治疗睑板腺功能障碍诱导的睑板腺型干眼以修复眼表的见解。
为了全面了解该领域的现有研究,使用PubMed、Medline、Scopus和Web of Science数据库进行了文献检索。本综述基于截至2024年6月的164篇出版物,使用关键词“外泌体”、“泪腺再生”、“泪腺功能障碍中的外泌体”进行了文献检索。
迄今为止的文献和研究表明,干细胞来源的外泌体和其他分泌因子在各种眼表疾病中对受损眼组织已显示出有益效果。外泌体所载物质通过促进泪液系统的内稳态在组织再生中发挥关键作用,而泪液系统内稳态在严重干眼病例中常常受到破坏。外泌体疗法作为一种再生疗法显示出前景,有可能解决干眼患者缺乏有效治愈性治疗的问题。
干细胞衍生的外泌体作为睑板腺型干眼的一种新的治疗选择,是一种有前景的创新方法。通过针对泪腺功能障碍并增强眼表修复,外泌体疗法在干眼疾病管理方面有取得重大进展的潜力。未来需要开展研究以完善该疗法的应用、优化递送方法,并充分了解其在恢复眼部健康方面的长期疗效。